Related Experiment Video
Updated: Sep 19, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Targeted treatment of hepatocellular carcinoma with aptamer-guided solid lipid nanoparticles loaded with
Yilin Xu1, Min Wang2, Jing Wu1
1School of Pharmacy, Hunan University of Chinese Medicine, Changsha, People's Republic of China.
Abstract:
Liver cancer is a common malignancy in the world, and its incidence and mortality rate are increasing year by year. The disease has a short course and a high mortality rate, posing a serious threat to humanity and health. The objective of this study is to create novel liver-targeted nanoparticles as a potential treatment for liver cancer. The aptamer (APS613-1) modified redox-sensitive norcantharidin solid lipid nanoparticles (Apt-PEG2000-ss-NCTD-SLNs) were prepared by emulsified ultrasonic dispersion method and characterized. The tumor targeting, antitumor effect and safety of the nanoparticles were investigated and evaluated in vitro and in vivo. The particle size of Apt-PEG2000-ss-NCTD-SLNs was 87.95 ± 3.32 nm, and the encapsulation efficiency was about 80.74 ± 2.36%, which had good biocompatibility. The results of in vitro experiments showed that, compared with unmodified solid lipid nanoparticles (NCTD-SLNs), Apt-PEG2000-ss-NCTD-SLNs had better targeting for liver tumor cells, and a stronger ability to inhibit cell proliferation and migration, as well as promote cell apoptosis. The in vivo results revealed that Apt-PEG2000-ss-NCTD-SLNs demonstrated good safety and anti-tumor efficacy, and its mechanism was achieved through the inhibition of cell proliferation and induction of apoptosis. The functionalized nanoparticles modified by aptamer APS613-1 can be used for the liver-targeted delivery of antitumor drugs for the treatment of liver cancer, and Apt-PEG2000-ss-NCTD-SLN is a potential drug for the treatment of liver cancer.
Insights
Novel aptamer-modified nanoparticles show promise for liver cancer treatment. These targeted nanoparticles effectively inhibit tumor growth and promote apoptosis, offering a potential new therapy for liver malignancy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Liver cancer presents a significant global health challenge with increasing incidence and mortality rates.
- Existing treatments often face limitations in efficacy and specificity, necessitating novel therapeutic strategies.
Purpose of the Study:
- To develop and characterize novel liver-targeted nanoparticles for enhanced liver cancer treatment.
- To evaluate the *in vitro* and *in vivo* efficacy and safety of aptamer-modified redox-sensitive norcantharidin solid lipid nanoparticles (Apt-PEG2000-ss-NCTD-SLNs).
Main Methods:
- Preparation of aptamer (APS613-1) modified redox-sensitive norcantharidin solid lipid nanoparticles (Apt-PEG2000-ss-NCTD-SLNs) using emulsified ultrasonic dispersion.
- Characterization of nanoparticle size (87.95 ± 3.32 nm) and encapsulation efficiency (80.74 ± 2.36%).
- Assessment of *in vitro* cellular targeting, proliferation inhibition, migration inhibition, and apoptosis induction, alongside *in vivo* anti-tumor efficacy and safety evaluations.
Main Results:
- Apt-PEG2000-ss-NCTD-SLNs exhibited superior targeting of liver tumor cells compared to unmodified nanoparticles.
- The functionalized nanoparticles demonstrated enhanced inhibition of cell proliferation and migration, and promoted apoptosis *in vitro*.
- *In vivo* studies confirmed good safety and significant anti-tumor efficacy, attributed to proliferation inhibition and apoptosis induction.
Conclusions:
- Aptamer-functionalized nanoparticles facilitate targeted delivery of anti-cancer drugs for liver cancer treatment.
- Apt-PEG2000-ss-NCTD-SLNs represent a promising therapeutic candidate for liver cancer, showcasing targeted delivery and potent anti-tumor activity.
More Related Videos
09:09Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
